ZEPBOUND KWIKPEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZEPBOUND KWIKPEN (ZEPBOUND KWIKPEN).
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It binds to and activates both GIP and GLP-1 receptors, leading to increased insulin secretion in a glucose-dependent manner, decreased glucagon secretion, delayed gastric emptying, and reduced appetite, thereby improving glycemic control and promoting weight loss.
| Metabolism | Tirzepatide is metabolized via proteolytic cleavage of the peptide backbone, beta-oxidation of the fatty diacid moiety, and amide hydrolysis. It is not significantly metabolized by CYP450 enzymes. |
| Excretion | Primarily renal and fecal following proteolytic degradation; intact peptide not detected in urine. Approximately 80% of total drug-related material is excreted in urine (mostly inactive metabolites) and 20% in feces (predominantly parent drug). |
| Half-life | Terminal elimination half-life is approximately 5 days (120 hours), supporting once-weekly subcutaneous dosing. Steady-state concentrations are achieved after 4 weeks of dosing. |
| Protein binding | Tirzepatide is >99% bound to plasma proteins, primarily to albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.6 L/kg, indicating distribution primarily in extracellular fluid and not extensive tissue binding. |
| Bioavailability | Subcutaneous: Absolute bioavailability is approximately 80% after abdominal injection. |
| Onset of Action | Subcutaneous: Onset of glucose-lowering effect within 2–3 hours post-dose; peak effect on gastric emptying occurs at 4–6 hours. |
| Duration of Action | Duration of clinical effect (glycemic control and weight loss) is approximately 1 week, consistent with once-weekly administration. Effects on gastric emptying persist for at least 24 hours post-dose. |
Subcutaneous injection once weekly. Initial dose: 2.5 mg for 4 weeks; then increase to 5 mg for at least 4 weeks; further increments of 2.5 mg every 4 weeks as tolerated up to maximum 15 mg once weekly.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment (eGFR ≥15 mL/min/1.73m²). Not studied in end-stage renal disease (eGFR <15 mL/min/1.73m²) or dialysis; use not recommended. |
| Liver impairment | No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use not recommended. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment recommended based on age alone. Consider renal function and comorbidities; monitor for adverse effects such as gastrointestinal intolerance and volume depletion. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZEPBOUND KWIKPEN (ZEPBOUND KWIKPEN).
| Breastfeeding | No human data. Tirzepatide is likely excreted in human milk due to molecular size and animal studies. The M/P ratio is unknown. Given the potential for severe adverse reactions in breastfed infants, including hypoglycemia and gastrointestinal effects, breastfeeding is not recommended during therapy and for at least one month after the last dose. |
| Teratogenic Risk | FDA Pregnancy Category N (not assigned). Animal studies with tirzepatide, the active ingredient, show embryo-fetal mortality and structural abnormalities at maternal exposures below the maximum human dose. First trimester exposure may be associated with increased risk of miscarriage and congenital malformations, though human data are insufficient. Second and third trimester exposure is associated with fetal growth restriction and possible adverse metabolic effects due to the GLP-1 receptor agonism. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)","Hypersensitivity to tirzepatide or any excipients","Not recommended for use in combination with other GLP-1 receptor agonists or GIP analogs"]
| Precautions | ["Risk of thyroid C-cell tumors (medullary thyroid carcinoma); advise patients of this risk and monitor for thyroid neoplasms","Acute pancreatitis: Discontinue if suspected; monitor for signs and symptoms","Hypoglycemia, particularly when used with insulin or insulin secretagogues; may require dose adjustment of concomitant antidiabetic therapy","Acute kidney injury: Monitor in patients with renal impairment or dehydration","Severe gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea) may lead to dehydration; consider discontinuation if intolerable","Diabetic retinopathy complications: Rapid improvement in glycemic control has been associated with worsening of retinopathy; monitor","Gallbladder disease (cholelithiasis, cholecystitis): Reported; consider if symptoms occur","Do not use in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2"] |
Loading safety data…
| Fetal Monitoring | Monitor fetal growth with serial ultrasound due to risk of fetal growth restriction. Monitor maternal glucose control and weight. Evaluate for signs of pancreatitis and thyroid C-cell tumors. If exposure occurs during pregnancy, consider fetal thyroid monitoring given animal findings. |
| Fertility Effects | In animal studies, tirzepatide caused disruption of estrous cycles and decreased fertility at clinically relevant exposures. In humans, weight loss and improved metabolic control may improve fertility in obese patients with polycystic ovary syndrome, but the direct drug effect on fertility is unknown. |